Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Current Leases: 2016-2025

Historic Current Leases for Enanta Pharmaceuticals (ENTA) over the last 7 years, with Sep 2025 value amounting to $3.1 million.

  • Enanta Pharmaceuticals' Current Leases rose 106.43% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 106.43%. This contributed to the annual value of $3.1 million for FY2025, which is 106.43% up from last year.
  • Enanta Pharmaceuticals' Current Leases amounted to $3.1 million in Q3 2025, which was up 31.41% from $2.4 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Current Leases' 5-year high stood at $5.4 million during Q2 2023, with a 5-year trough of $1.0 million in Q4 2024.
  • For the 3-year period, Enanta Pharmaceuticals' Current Leases averaged around $3.3 million, with its median value being $3.1 million (2025).
  • Per our database at Business Quant, Enanta Pharmaceuticals' Current Leases soared by 106.54% in 2023 and then crashed by 79.74% in 2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Current Leases (Quarterly) stood at $3.5 million in 2021, then rose by 0.49% to $3.5 million in 2022, then soared by 42.46% to $5.0 million in 2023, then slumped by 79.74% to $1.0 million in 2024, then spiked by 106.43% to $3.1 million in 2025.
  • Its Current Leases stands at $3.1 million for Q3 2025, versus $2.4 million for Q2 2025 and $2.2 million for Q1 2025.